Chronic to episodic migraine reversion with fremanezumab use: post hoc analysis of the HALO CM trial

Takeaway

  • Quarterly and monthly fremanezumab treatment for 3 months resulted in a reduced number of headache days during treatment in a greater number of people who reverted from chronic migraine (CM) to episodic migraine (EM) compared with those who received placebo.

Why this matters

    Compared with EM, CM results in higher rates of comorbidities, medication overuse, and disability. The reversion from CM to EM is a meaningful treatment goal for people with CM as it may offer clinical benefit and improve quality of life.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.